ATCVet Code: QS02CA06
Pharmacodynamics
The veterinary medicinal product combines three active ingredients:
- Marbofloxacin, a synthetic bactericidal agent belonging to the fluoroquinolone family that acts by inhibiting DNA gyrase. It exhibits a broad spectrum of activity against Gram-positive bacteria (e.g. Staphylococcus intermedius) and against Gram-negative organisms (Pseudomonas aeruginosa, Escherichia coli and Proteus mirabilis).
- Clotrimazole, an anti-fungal agent that belongs to the imidazole family and which acts by causing changes in membrane permeability, allowing intracellular compounds to leak from the cell and thus inhibiting cellular molecular synthesis. It exhibits a wide spectrum of activity and is aimed, in particular, at Malassezia pachydermatis;
- Dexamethasone acetate, a synthetic glucocorticoid exhibiting anti- inflammatory and anti-pruritic activity.
Pharmacokinetics
Pharmacokinetics studies in dogs at the therapeutic dosage have shown that:
Marbofloxacin plasma concentrations peak at 0.06 µg/ml on the 14th day of treatment.
Marbofloxacin bonds weakly to plasma proteins (< 10% in dogs) and is eliminated slowly, mainly in the active form, over 2/3 in urine and over 1/3 in fæces.
Clotrimazole absorption is extremely poor (plasma concentration < 0.04 µg/ml).
Dexamethasone acetate plasma concentration reaches 1.25 ng/ml on the 14th day of treatment. Dexamethasone resorption is not increased by the inflammatory process induced by otitis.